How was the proposed market commitment of $3bn calibrated?
This is the estimated market revenue for the average product in a sample of recently developed commercial pharmaceuticals. In other words, this is the amount of sales revenues that has been large enough to spur R&D investments for existing products – so it is reasonable to conclude that it is large enough to stimulate R&D investment in diseases concentrated in developing countries. We recommend that further analysis be undertaken to confirm this analysis of average market sizes with alternative data sets on sales revenues.
